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The RANK/RANKL/OPG signalling pathway is essential for osteoclastogenesis.
Osteoprotegerin (OPG) is a decoy receptor for RANKL. By binding to RANKL, OPG blocks RANKL-RANK
interaction, inhibiting the differentiation of the osteoclast precursor into a mature osteoclast and
thereby protecting the skeleton from excessive bone resorption.
• Auto-antibodies against Osteoprotegerin (α-OPGAb), by capturing OPG, enable sustained
interaction of RANKL with RANK and over-activation of osteoclasts.
• Such antibodies were identified in 2009, in a man with coeliac disease associated with severe
osteoporosis1 and later in 2013, in patients presenting with rheumatoid arthritis, systemic lupus
erythematosus, spondyloarthritis and osteoporosis2.
• These findings suggest a role for α-OPGAb as primary cause of high bone turnover.
We developed an enzyme linked immunosorbent assay (ELISA) for detection and quantification of α-
OPGAb in patient serum samples3 showing α-OPGAb to be present in 14% of an apparently healthy
young adult population.
Bone resorption is increased in the elderly, particularly in women who may demonstrate increased α-
OPGAb.
We aimed to define a reference range for OPG autoantibodies in non-osteoporotic post-menopausal
women.
Introduction: autoantibodies for OPG in the 
RANK-RANKL-OPG signalling pathway
Conclusions
Norwich Medical School
 Skewed distribution of a-OPGAb in both populations
 Adult population would be considered positive with a titer above the cut-off 
limit (95%) of 191ng/mL calculated using the geometric mean of log10 
dataset
 The reference ranges obtained were 134-191ng/mL and 131-184ng/mL 
for control and post-menopausal women, respectively. 
We established that the population of normal post-menopausal women who do not have osteoporosis also do not have elevated concentrations of α-OPGAb when compared to
a younger female population (18-26 yrs). This suggest that α-OPGAb is not positively associated with increasing age suggesting that the increased production of α-OPGAb is
mainly related to pathologic conditions which can result in significant bone resorption.
Comparison of osteoporotic patient samples to non-osteoporotic post-menopausal women would be interesting to determine whether α-OPGAb can be used to detect patients
at high risk of bone resorption and identify appropriate treatment for this particular subgroup of patients.
We are designing a humanized antibody against human OPG in order to eliminate false positive.
Corresponding author: i.piec@uea.ac.uk
Method: α-OPGAb assay on serum samples
Schematic of a-OPGAb assay principle.
 Samples
• Serum samples from non-osteoporotic 60-65yr-old post-menopausal women
(ANSAVID study4, n=134)
• Serum samples from healthy volunteers following and in accordance with the
Ministry of Defence Research Ethics Committee (MODREC-165) (18-26yrs, n=51).
 ELISA:
• Plates (Maxisorp, ThermoFisher Scientific) were coated with 0.5µg/mL recombinant
OPG (Novoprotein)
• Samples/standards (rabbit OPGab, Abnova) and controls (50µL) were incubated for
3hrs at RT
• A two-step detection was used: goat polyclonal biotin conjugated anti-human OPG
antibody (ThermoFisher Scientific) and Streptavidin conjugated horseradish
peroxidase (Jackson ImmunoResearch).
• TMB (Sigma Aldrich) was used as substrate and signal was measure using a
Multiskan software linked to a plate reader (ThermoFisher Scientific). Circulating
antibody concentration is calculated against a 4-Parameter Logistic equation
(Typical obtained using a polyclonal r2=0.9916).
Results: Distribution of α-OPGAb
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Distribution of samples a-OPGAb concentration in healthy young (red) 
and postmenopausal (blue) women
RANK/RANKL/OPG signalling pathway and role of α-OPGAb.
Adapted from Boyle WJ, et al. Nature 2003 423(6937):337-425
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concentration ranges [α-OPGAb] (ng/mL)
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